Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free CYTK Stock Alerts $70.11 -1.30 (-1.82%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$69.96▼$71.8650-Day Range$63.75▼$84.8052-Week Range$25.98▼$110.25Volume1.61 million shsAverage Volume3.51 million shsMarket Capitalization$7.22 billionP/E RatioN/ADividend YieldN/APrice Target$77.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside9.8% Upside$77.00 Price TargetShort InterestBearish14.91% of Float Sold ShortDividend StrengthN/ASustainability-0.94Upright™ Environmental ScoreNews Sentiment1.19Based on 6 Articles This WeekInsider TradingSelling Shares$10.04 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.51) to ($3.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector328th out of 938 stocksPharmaceutical Preparations Industry144th out of 420 stocks 2.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $77.00, Cytokinetics has a forecasted upside of 9.8% from its current price of $70.11.Amount of Analyst CoverageCytokinetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.91% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cytokinetics has recently increased by 1.86%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 69.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.94. Previous Next 2.9 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Cytokinetics this week, compared to 6 articles on an average week.Search InterestOnly 15 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows12 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,035,950.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.51) to ($3.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -12.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -12.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesMarch 27, 2024 | msn.comCytokinetics gains amid renewed takeover speculationMarch 25, 2024 | globenewswire.comCytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific SessionMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | finance.yahoo.comCYTK Mar 2024 63.000 callMarch 15, 2024 | finance.yahoo.comCYTK Mar 2024 69.000 putMarch 15, 2024 | finance.yahoo.comCYTK Mar 2024 69.000 callMarch 15, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Amedisys (AMED), Cytokinetics (CYTK) and Coherus Biosciences (CHRS)March 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 15, 2024 | finance.yahoo.comCYTK Mar 2024 62.000 callMarch 15, 2024 | finance.yahoo.comCYTK Apr 2024 58.000 putMarch 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Coherus Biosciences on Strong Sales and Strategic RestructuringMarch 13, 2024 | investorplace.com7 Biotech Stocks to Buy as Sector Rotation Ramps UpMarch 13, 2024 | seekingalpha.comIonis stock jumps as MASH drug succeeds in mid-stage trialMarch 12, 2024 | ca.finance.yahoo.comCYTK Aug 2024 30.000 putMarch 12, 2024 | finance.yahoo.comCYTK Mar 2024 61.000 putMarch 12, 2024 | finance.yahoo.comQ4 2023 CytomX Therapeutics Inc Earnings CallMarch 11, 2024 | finance.yahoo.comCYTK Apr 2024 65.000 putMarch 11, 2024 | finance.yahoo.comCYTK Apr 2024 110.000 callMarch 10, 2024 | finance.yahoo.comCYTK Apr 2024 73.000 callMarch 10, 2024 | finance.yahoo.comCYTK Apr 2024 72.000 putMarch 9, 2024 | finance.yahoo.comCYTK Mar 2024 83.500 callMarch 9, 2024 | finance.yahoo.comCYTK Mar 2024 72.000 putMarch 7, 2024 | finance.yahoo.comCYTK Mar 2024 68.000 callMarch 4, 2024 | globenewswire.comCytokinetics to Participate in March Investor ConferencesMarch 1, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | markets.businessinsider.comOptimistic Outlook on Cytokinetics: Buy Rating Affirmed Amid Anticipated Growth and Strategic MilestonesSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$77.00 High Stock Price Target$108.00 Low Stock Price Target$42.00 Potential Upside/Downside+9.8%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-6,988.63% Pretax Margin-6,988.63% Return on EquityN/A Return on Assets-65.08% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$7.53 million Price / Sales959.01 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-17.79Miscellaneous Outstanding Shares103,000,000Free Float99,091,000Market Cap$7.22 billion OptionableOptionable Beta0.69 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President & Director Comp: $1.14MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $463.75kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $776.99kMr. Andrew M. Callos (Age 68)Executive VP & Chief Commercial Officer Comp: $745.4kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Supply Chain Operations & Technical Operations Ms. Diane WeiserSenior Vice President of Corporate Communications & Investor RelationsMs. Kari K. Loeser J.D.VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZApellis PharmaceuticalsNASDAQ:APLSCerevel TherapeuticsNASDAQ:CEREElanco Animal HealthNYSE:ELANViking TherapeuticsNASDAQ:VKTXView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 32,400 shares on 3/27/2024Ownership: 0.000%PNC Financial Services Group Inc.Sold 517 shares on 3/22/2024Ownership: 0.007%Vanguard Group Inc.Bought 273,565 shares on 3/11/2024Ownership: 10.696%Fisher Asset Management LLCBought 536,046 shares on 3/5/2024Ownership: 0.520%Fady Ibraham MalikSold 32,604 sharesTotal: $2.20 M ($67.56/share)View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 equities research analysts have issued 1-year price objectives for Cytokinetics' shares. Their CYTK share price targets range from $42.00 to $108.00. On average, they predict the company's share price to reach $77.00 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK shares have decreased by 16.0% and is now trading at $70.11. View the best growth stocks for 2024 here. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) posted its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to analyst estimates of $7.62 million. Cytokinetics's quarterly revenue was down 10.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.45) earnings per share. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), American Century Mid Cap Growth Impact (MID), Fidelity Disruptive Medicine ETF (FMED), BNY Mellon Innovators ETF (BKIV), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO) and Principal Healthcare Innovators ETF (BTEC). What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (11.24%), Vanguard Group Inc. (10.70%), Price T Rowe Associates Inc. MD (3.31%), RTW Investments LP (2.58%), Northern Trust Corp (1.08%) and First Turn Management LLC (0.82%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.